Glad­stone spin­out Tenaya tack­les new cures for heart fail­ure with $50M A round

The idea that a fresh source of re­gen­er­a­tive cells could re­pair a dam­aged heart has dri­ven a va­ri­ety of large­ly un­suc­cess­ful re­search ef­forts aimed at help­ing pa­tients who have suf­fered from heart at­tacks and strokes. But now The Col­umn Group is bankrolling a $50 mil­lion Se­ries A for an up­start biotech that hopes to do just that.

The biotech is called Tenaya Ther­a­peu­tics, the brain­child in part of Deep­ak Sri­vas­ta­va, MD, di­rec­tor of the San Fran­cis­co-based Glad­stone In­sti­tute of Car­dio­vas­cu­lar Dis­ease and a co-founder of the new com­pa­ny.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.